Assenagon Asset Management S.A. Reduces Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Assenagon Asset Management S.A. decreased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 83.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 591,679 shares of the biotechnology company’s stock after selling 2,882,776 shares during the period. Assenagon Asset Management S.A.’s holdings in ADMA Biologics were worth $10,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Hollencrest Capital Management bought a new stake in ADMA Biologics during the third quarter valued at about $30,000. Larson Financial Group LLC bought a new position in shares of ADMA Biologics in the third quarter worth about $31,000. National Bank of Canada FI purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at about $35,000. GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 967 shares during the period. Finally, Quest Partners LLC purchased a new stake in ADMA Biologics in the 2nd quarter worth approximately $29,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 3.70% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. HC Wainwright lifted their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James upped their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

ADMA Biologics Stock Down 3.7 %

NASDAQ ADMA opened at $16.02 on Friday. ADMA Biologics, Inc. has a 12 month low of $4.86 and a 12 month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The stock has a market cap of $3.79 billion, a PE ratio of 57.21 and a beta of 0.76. The stock’s 50 day moving average is $19.04 and its 200 day moving average is $17.29.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the firm earned $0.01 earnings per share. Research analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.